Dyadic International, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 12, 2020 at 04:25 pm EST
Share
Dyadic International, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 2.576 million compared to USD 1.943 million a year ago. Net loss was USD 2.499 million compared to USD 1.698 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to USD 0.06 a year ago. For the nine months, operating loss was USD 7.756 million compared to USD 7.346 million a year ago. Net loss was USD 7.365 million compared to USD 6.569 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.24 a year ago. Operating loss was USD 2.576 million compared to USD 1.943 million a year ago. Net loss was USD 2.499 million compared to USD 1.698 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to USD 0.06 a year ago. Operating loss was USD 7.756 million compared to USD 7.346 million a year ago. Net loss was USD 7.365 million compared to USD 6.569 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.24 a year ago.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
DYADIC INTERNATIONAL, INC. 
